Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Arsenic Trioxide and Azacitidine for NPM1-Mutated AML MRD
NCT04689815Phase 2Unknown
- Sponsor
- The University of Hong Kong
- Start
- Jan 2021
- Primary completion
- Dec 2023
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of arsenic trioxide in acute myeloid leukemia (AML), sponsored by The University of Hong Kong. Status: unknown.
02
Drugs
arsenic trioxide
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04689815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04689815.